Today's cancer landscape is rapidly transforming. As patients living with cancer are being diagnosed younger and living longer, our goal is to reimagine cancer care to help meet this next generation of patients’ needs.1,2

We’re committed to delivering innovative approaches through meaningful collaboration. By fostering relationships with patient advocacy organizations, research institutions, and health care systems, we aim to support initiatives that emphasize and enable earlier detection, and enhance diagnosis—working toward more informed communities.

By carefully harnessing advancing scientific innovation alongside community partnerships, our focus is on developing collaborations that support patients in maintaining their identities and lifestyles throughout their cancer journey.

Areas of focus

Approximately 1 in 8 women (13%) in the United States will develop breast cancer (BC) at some point in their life, making it the most common cancer diagnosed among women in the United States.

With a deep understanding of the mechanism of the disease, and by listening and working with the patient community and those who care for them, we aspire to continue reimagining medicine for people touched by it.

Learn More(link is external)

Prostate cancer (PC) is the most common cancer among men, after skin cancer.4 At Novartis, we are focused on addressing the multi-faceted needs of people living with prostate cancer as they navigate this difficult disease.

Learn More(link is external)

Revolutionary therapies have transformed Chronic Myeloid Leukemia (CML), a type of blood cancer, into a chronic disease.5 However, many newly diagnosed patients do not meet their treatment goals and discontinue or change treatment due to intolerance.6 Patients need options that enable them to achieve meaningful outcomes while navigating a long-term, chronic illness.

Learn More(link is external)

Two women looking at a phone

Learn How Novartis is Connecting Patients to Pioneering Care at ASCO

Meeting the needs of the next generation patient requires fundamentally rethinking how we develop treatments and engage with patients. See the work we're doing in other key areas of oncology.

References

  1. Jianhui Zhao, Liying Xu, Jing Sun. et al. BMJ Oncology. 2023. doi: 2:e000049.2
  2. Kadambi S, Loh KP, Dunne R. et al. Nat Rev Clin Oncol. 2020 Dec;17(12):742- 755. doi: 10.1038/s41571-020-0421-z
  3. American Cancer Society. 2024.
  4. American Cancer Society. Assessed June 27, 2024. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html.(link is external)
  5. Novartis, 2021. Accessed September 6, 2023. http://www.novartis.com/news/novartis-hematology-relentless-pursuit-cure(link is external)
  6. Claudiani S, Chughtai F, Khan A. et al. Leukemia. 2024;38:796 - 802. doi:10.1038/s41375-024-02187-w
  7. Christoph Soerensen SJ, Montez-Rath ME, Chung BI. et al. MP68-08 Journal of Urology. 2024; 211(5S):e1110. doi:10.1097/01.JU.0001008744.60568.e8.08